Intolerance to roflumilast in real-life clinical practice.
作者信息
Gómez-Rodríguez Mónica, Golpe Rafael
机构信息
Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain.
Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain.
出版信息
Eur J Intern Med. 2017 Sep;43:e28-e29. doi: 10.1016/j.ejim.2017.04.019. Epub 2017 May 2.
PMID:28476325
Abstract
摘要
相似文献
1
Intolerance to roflumilast in real-life clinical practice.在实际临床实践中对罗氟司特不耐受。
Eur J Intern Med. 2017 Sep;43:e28-e29. doi: 10.1016/j.ejim.2017.04.019. Epub 2017 May 2.
2
Roflumilast for chronic obstructive pulmonary disease.罗氟司特用于慢性阻塞性肺疾病
Lancet. 2005 Nov 26;366(9500):1845-6; author reply 1846-7. doi: 10.1016/S0140-6736(05)67748-3.
3
[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].[罗氟司特：慢性阻塞性肺疾病炎症治疗新选择的临床综述]
Arch Bronconeumol. 2010 Nov;46 Suppl 9:8-11. doi: 10.1016/S0300-2896(10)70047-8.
4
Roflumilast (Daliresp) for COPD.罗氟司特（达力释）用于慢性阻塞性肺疾病。
Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60.
5
What is the role of roflumilast in chronic obstructive pulmonary disease?罗氟司特在慢性阻塞性肺疾病中起什么作用？
Cleve Clin J Med. 2017 Jan;84(1):13-15. doi: 10.3949/ccjm.84a.15150.
6
[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].罗氟司特：慢性阻塞性肺疾病治疗的新方法
Med Monatsschr Pharm. 2010 Jul;33(7):236-43.
7
The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.监管机构对罗氟司特的不同意见令人费解，但我们需要治疗慢性阻塞性肺疾病的新药。
Ther Adv Respir Dis. 2010 Aug;4(4):195-8. doi: 10.1177/1753465810377636.
8
Roflumilast: A Review in COPD.罗氟司特：在 COPD 中的应用评价。
Drugs. 2015 Sep;75(14):1645-56. doi: 10.1007/s40265-015-0463-1.
9
Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.减轻疾病负担并改善肺功能——罗氟司特：获批用于中重度慢性阻塞性肺疾病：临床护理专家的最新资讯
Clin Nurse Spec. 2011 Jul-Aug;25(4):176-7. doi: 10.1097/NUR.0b013e31822229a9.
10
Roflumilast for severe COPD?罗氟司特用于重度慢性阻塞性肺疾病？
Drug Ther Bull. 2011 Apr;49(4):45-8; quiz iii-iv. doi: 10.1136/dtb.2011.02.0025.
引用本文的文献
1
Phosphodiesterase Inhibition as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease: Where We Have Been and What Lies Ahead.磷酸二酯酶抑制作为慢性阻塞性肺疾病的一种治疗策略：我们的历程与未来方向
Chronic Obstr Pulm Dis. 2025 Jan 29;12(1):82-92. doi: 10.15326/jcopdf.2024.0559.
2
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.在 COPD 中新型吸入型 PDE4 抑制剂 CHF6001 的疗效和安全性：PIONEER 研究。
Respir Res. 2020 Sep 22;21(1):246. doi: 10.1186/s12931-020-01512-y.
3
Efficacy and safety profile of roflumilast in a real-world experience.罗氟司特在真实世界中的疗效和安全性概况。
J Thorac Dis. 2019 Apr;11(4):1100-1105. doi: 10.21037/jtd.2019.04.49.
4
Effects of Roflumilast on Rehospitalization and Mortality in Patients.罗氟司特对患者再住院率和死亡率的影响。
Chronic Obstr Pulm Dis. 2018 Dec 20;6(1):74-85. doi: 10.15326/jcopdf.6.1.2018.0139.
5
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.用于治疗炎症性疾病的磷酸二酯酶-4抑制剂
Front Pharmacol. 2018 Oct 17;9:1048. doi: 10.3389/fphar.2018.01048. eCollection 2018.
Zotero 插件